Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer

Pediatric Pulmonology
Jennifer S GuimbellotSteven M Rowe

Abstract

The CFTR potentiator ivacaftor is responsible for significant clinical improvements among a subset of patients with cystic fibrosis. Because it is a substrate of the cytochrome P450 system, specifically CYP3A4/5, ivacaftor is subject to significant drug-drug interactions, including due to commonly used antimicrobials such as rifampin. While the interaction of rifampin and ivacaftor has been examined in vitro, severe adverse events resulting from this interaction have not been reported in the literature. In this report, we describe the termination of steady, long-term improvement in a patient taking ivacaftor, resulting from the use of rifampin and precipitating a significant pulmonary exacerbation.

References

May 18, 2016·The Lancet. Respiratory Medicine·George M SolomonSteven M Rowe
Sep 24, 2016·Pediatric Pulmonology·Cameron L JordanMarianna M Henry

❮ Previous
Next ❯

Citations

May 21, 2019·Pediatric Pulmonology·Adrienne P Savant, Susanna A McColley
Dec 11, 2019·Pediatric Pulmonology·Stacey L MartinianoLindsay J Caverly
Mar 7, 2019·International Journal of Impotence Research·Pramod KrishnappaJuan Ignacio Martinez-Salamanca
Dec 21, 2019·American Journal of Respiratory and Critical Care Medicine·Marcus A MallSteven M Rowe
Jan 12, 2021·Expert Opinion on Drug Delivery·Douweh Leyla Gbian, Abdelwahab Omri
May 15, 2021·Frontiers in Pharmacology·Marjolein EnsinckMarianne S Carlon
Aug 16, 2021·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·James M CleggAndrew G Sokolow

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Clinical Pharmacology and Therapeutics
K VillikkaP J Neuvonen
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
A KostyukA Akanov
American Journal of Respiratory and Critical Care Medicine
Don HayesShahid I Sheikh
© 2022 Meta ULC. All rights reserved